Drug Development – Page 2

Creative Biolabs Sets the Bar Higher in Human Antibody Discovery with Cutting-Edge Platforms

1 month ago talkbio0Tagged AI-driven, antibody libraries, Creative Biolabs, Discover, Drug Development, Generative AI, human antibody, platforms

Creative Biolabs; human antibody discovery; AI-driven platforms; generative AI; antibody libraries; drug development

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

2 months ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Former FDA Deputy Dr. Namandjé N. Bumpus to Lead Charles River’s New Scientific Advisory Board

2 months ago talkbio0Tagged alternative testing, Animal Welfare, biopharmaceutical innovation, Charles River Laboratories, Drug Development, Namandjé Bumpus, NAMs, New Approach Methodologies, Scientific Advisory Board, United States Food and Drug Administration

Namandjé Bumpus; Charles River Laboratories; Scientific Advisory Board; FDA; New Approach Methodologies; NAMs; alternative testing; drug development; animal welfare; biopharmaceutical innovation

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

3 months ago talkbio0Tagged ANGPTL3, Biopharma, biotech collaboration, cardiovascular pipeline, Drug Development, Dyslipidemias, milestone payments, Novartis, RNA Interference, RNA, Small Interfering

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments

Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile

3 months ago talkbio0Tagged benefit-risk profile, Clinical Trials, Dose-Limiting, Drug Development, Malignant Neoplasms, mesothelin, T-Cell engager, Toxicity aspects, ZW171, Zymeworks

Zymeworks; ZW171; T-cell engager; mesothelin; cancer; clinical trial; drug development; benefit-risk profile; dose-limiting toxicity

Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M

3 months ago talkbio0Tagged AI drug design, charmed, Drug Development, Leukemia, Myelocytic, Acute, Menin Inhibitor, NVIDIA, Series B funding, venture capital, Wugen

CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development

Who Is Making AI Work in Drug R&D in 2025?

3 months ago talkbio0Tagged Advice, Artificial Intelligence, Big Pharma, biopharma startups, Clinical Trials, Drug Development, Efficiency, Precision Medicine, United States Food and Drug Administration

AI drug discovery; Big Pharma; biopharma startups; clinical trials; FDA guidance; personalized medicine; drug development efficiency

Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration

4 months ago talkbio0Tagged Billion Collaboration, Drug Development, Merck KGaA, milestone payments, nervous system disorder, RNA-targeting, royalties, Skyhawk, SkySTAR platform

Merck KGaA; Skyhawk Therapeutics; RNA-targeting; SkySTAR platform; neurological disorders; $2 billion collaboration; drug development; milestone payments; royalties